Vertex Pharmaceuticals Inc. said Thomas Graney resigned as CFO of the company.

Graney will continue as an employee of the company and will help in the transition until February 2019.

Ian Smith, the company's executive vice president, COO and former CFO, will act as interim CFO.

Boston-based Vertex develops therapies for various diseases, including cystic fibrosis, beta-thalassemia and sickle cell disease.